New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 27, 2014
13:30 EDTBCRX, DYAXBioCryst data has favorable read through for Dyax, says Jefferies
After Biocryst (BCRX) reported positive data from a trial evaluating BCX4161 in hereditary angioedema, Jefferies said the study results point to higher odds for the success of Dyax's (DYAX) DX-2930, which has a similar pathway and is being developed as a prophylactic treatment for HAE. The firm maintains its Buy rating and $13.00 price target on Dyax.
News For DYAX;BCRX From The Last 14 Days
Check below for free stories on DYAX;BCRX the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 18, 2014
12:08 EDTBCRXBioCryst receives additional NIAID funding for BCX4430
BioCryst announced that the National Institute of Allergy and Infectious Diseases exercised two additional options under its contract, which provides for GMP drug substance and drug product manufacture of BCX4430. Exercise of these options includes up to a $2M increase to the existing development contract. The contract modification and the two additional options exercised represent up to $4M to BioCryst in order to accelerate the development of BCX4430 as a treatment for hemorrhagic fever viruses, including Ebola virus and Marburg virus disease. NIAID, part of the National Institutes of Health, granted this five year term contract to BioCryst in September 2013. Approximately $19.9M of funding has been awarded to date under the contract. With this additional award, the BCX4430 development contract has been increased in value to $26.3M, if all options are exercised. This project is funded in whole or in part with Federal funds from the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services, under Contract No. HHSN272201300017C.
September 15, 2014
07:03 EDTDYAXDyax announces issuance of two DX-2930 U.S. patents
Subscribe for More Information
September 7, 2014
12:42 EDTBCRXBioCryst announces RAPIVAB trial results for the treatment of influenza
Subscribe for More Information
September 5, 2014
10:57 EDTBCRXBioCryst falls after WHO posts document on potential Ebola therapies
Shares of BioCryst Pharmaceuticals (BCRX) are sliding in early trading after the World Health Organization posted documents ahead of a meeting it is holding to discuss the recent Ebola outbreak and potential strategies to combat the disease. WHAT'S NEW: This week, on September 4-5, WHO is bringing together technical experts from the groups developing Ebola interventions along with people working to overcome Ebola virus disease, the group stated on its website. WHAT'S NOTABLE: In a background document on potential Ebola therapies and vaccines, WHO wrote regarding the availability and feasibility of BCX4430 from Biocryst that the drug "needs animal treatment and protection data for EVD before it can be considered. No material is currently available for field use." PRICE ACTION: Shares of BioCryst are down 50c, or 3.76%, to $12.28. Reference Link

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use